Key facts
- This page summarizes Stephen Hoge's Form 4 filing for Moderna, Inc. (MRNA).
- 8 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 16 May 2022, 16:09.
Stephen Hoge - 12 May 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- President
- Issuer ticker
- MRNA
- Reported as of
- 12 May 2022
- Net transaction value
- -$2,476,950
- SEC form
- 4
- Accepted by SEC
- 16 May 2022, 16:09:15 UTC
- Prior SEC filing
- 11 May 2022
- Next SEC filing
- 25 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Hoge filed Form 4 for Moderna, Inc. (MRNA) on 16 May 2022.
Change
- Previous filing in this sequence was filed on 11 May 2022.
- Current net transaction value: -$2,476,950.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $54,500
- Shares
- +5,000
- Change %
- +0.31%
- Price
- $10.90*
- Shares after
- 1,627,820
- Date
- 12 May 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $605,500
- Shares
- -5,000
- Change %
- -0.31%
- Price
- $121.10
- Shares after
- 1,622,820
- Date
- 12 May 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $54,500
- Shares
- +5,000
- Change %
- +0.31%
- Price
- $10.90*
- Shares after
- 1,627,820
- Date
- 13 May 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $9,900
- Shares
- +10,000
- Change %
- +0.61%
- Price
- $0.9900*
- Shares after
- 1,637,820
- Date
- 13 May 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $1,990,350
- Shares
- -15,000
- Change %
- -0.92%
- Price
- $132.69
- Shares after
- 1,622,820
- Date
- 13 May 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,116
- Date
- 12 May 2022
- Ownership
- By Valhalla, LLC
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 151,933
- Date
- 12 May 2022
- Ownership
- By Trust
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -5.7%
- Price
- $0.000000
- Shares after
- 81,972
- Date
- 12 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $10.90
- Footnotes
- F1, F3
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -6.1%
- Price
- $0.000000
- Shares after
- 76,972
- Date
- 13 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $10.90
- Footnotes
- F1, F3
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -57%
- Price
- $0.000000
- Shares after
- 7,431
- Date
- 13 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $0.9900
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
Footnote F2
These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F3
This option is fully vested and exercisable.